Delta 9 Cannabis Inc
TSX:DN

Watchlist Manager
Delta 9 Cannabis Inc Logo
Delta 9 Cannabis Inc
TSX:DN
Watchlist
Price: 0.01 CAD Market Closed
Market Cap: 3.5m CAD

EV/EBITDA
Enterprise Value to EBITDA

-36.3
Current
-34
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-36.3
=
Enterprise Value
26.8m CAD
/
EBITDA
-736.7k CAD
EBITDA Growth EV/EBITDA to Growth
CA
Delta 9 Cannabis Inc
TSX:DN
Average EV/EBITDA: 436.6
Negative Multiple: -36.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
13%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.5
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-23.6
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A